Incretin analogues, such as GLP-1 receptor (GLP-1R) agonists (including semaglutide and liraglutide, among others) have gained widespread attention due to their success in the treatment of type 2 diabetes mellitus and obesity. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.